Please ensure Javascript is enabled for purposes of website accessibility

Why Biogen Stock Is on Fire Today

By George Budwell - Oct 22, 2019 at 8:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Biogen's shares are getting a boost from a pair of catalysts this morning.

What happened

Biotech heavyweight Biogen (BIIB 0.97%) saw its shares rise by as much as 43.7% in premarket trading Tuesday morning. The biotech's stock caught fire in early action in response to a pair of catalysts:

1. Biogen shocked the industry this morning by announcing that it plans on pursuing a regulatory application for the Alzheimer's disease candidate aducanumab in the United States. This high-value drug candidate was widely thought to be destined for the scrap pile after flaming out in twin late-stage trials earlier this year.

2. The biotech also released its 2019 third-quarter earnings ahead of the bell this morning. On this front, Biogen handily beat FactSet's consensus estimates for both earnings per share and revenue for the three-month period, giving investors another solid reason to bid up the company's shares.

So what

Biogen's decision to sally forth with an aducanumab regulatory filing in early 2020 reportedly centers around a new data analysis. The company said that this analysis showed that early Alzheimer's disease patients receiving the high-dose treatment of aducanumab exhibited a statistically significant reduction in clinical decline at week 78.

A medical form with Alzheimer's Disease printed in bold at the top.

Image Source: Getty Images.

In regard to the biotech's Q3 report, Biogen's better-than-expected multiple sclerosis revenue for the three-month period, combined with skyrocketing Spinraza sales, were the primary drivers behind this earnings beat.

Now what

Biogen has been kicking the can down the road on a possible bolt-on acquisition for several years at this point. Today's aducanumab news is almost certainly the reason behind the company's hesitation to pursue such a costly business development move.

The long and short of it is that aducanumab would be a game changer for the biotech from a revenue-generation standpoint. That said, the drug's regulatory review is anything but a slam dunk. Investors might want to think twice before chasing this red-hot biotech stock today.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$206.20 (0.97%) $1.98

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.